Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Bamlanivimab  COVID-19 treatment studies for Bamlanivimab  C19 studies: Bamlanivimab  Bamlanivimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Bamlanivimab for COVID-19: real-time meta analysis of 11 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19ly.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) 74% 0.26 [0.09-0.75] hosp. 5/309 9/143 Improvement, RR [CI] Treatment Control Gottlieb (RCT) 71% 0.29 [0.09-0.96] hosp./ER 4/101 7/52 Gottlieb (RCT) 80% 0.20 [0.03-1.56] hosp./ER 1/37 7/52 Gottlieb (RCT) 75% 0.25 [0.03-1.92] hosp./ER 1/30 7/52 Gottlieb (RCT) 56% 0.44 [0.10-1.98] hosp./ER 2/34 7/52 Gottlieb (RCT) 92% 0.08 [0.00-1.39] hosp./ER 0/31 7/52 Lilly (DB RCT) 92% 0.08 [0.00-1.43] death 0/511 4/258 Lilly (DB RCT) 87% 0.13 [0.05-0.40] hosp./death 4/511 15/258 Webb 80% 0.20 [0.03-1.46] death 1/479 57/5,536 Webb 53% 0.47 [0.31-0.72] hosp. 22/479 538/5,536 Webb 27% 0.73 [0.65-0.82] hosp./ER 65/479 1,018/5,536 Cooper 45% 0.55 [0.07-3.99] death 1/473 33/8,534 Cooper 58% 0.42 [0.10-1.72] ICU 2/473 85/8,534 Cooper 5% 0.95 [0.69-1.30] hosp. 37/473 703/8,534 Cooper -17% 1.17 [0.59-2.32] death 11/2,427 33/8,534 Cooper 9% 0.91 [0.57-1.45] ICU 22/2,427 85/8,534 Cooper 28% 0.72 [0.61-0.86] hosp. 144/2,427 703/8,534 Rubin 97% 0.03 [0.00-0.25] death 1/191 10/1,066 Rubin 65% 0.35 [0.12-0.94] hosp. 16/191 121/1,065 ACTIV-3/T.. (RCT) -100% 2.00 [0.69-5.83] death 9/163 5/151 Bariola 67% 0.33 [0.10-1.01] death 4/234 12/234 Bariola 64% 0.36 [0.20-0.61] hosp./death 16/234 45/234 Bariola 61% 0.39 [0.22-0.70] hosp. 15/234 39/234 Ganesh 74% 0.26 [0.05-1.20] death 2/1,789 8/1,832 Ganesh 49% 0.51 [0.24-1.09] ICU 10/1,789 20/1,832 Ganesh 37% 0.63 [0.43-0.91] hosp. 44/1,789 72/1,832 Chew (RCT) 25% 0.75 [0.26-2.10] hosp. 6/159 8/158 Chew (RCT) 52% 0.48 [0.09-2.49] hosp. 2/48 4/46 Chew (RCT) -1% 1.01 [0.26-3.93] hosp. 4/111 4/112 Chew (RCT) -14% 1.14 [0.00-455] recov. time 48 (n) 46 (n) Chew (RCT) -17% 1.17 [0.98-1.40] recov. time 111 (n) 112 (n) Chew (RCT) 26% 0.74 [0.62-0.90] viral load 48 (n) 46 (n) Chew (RCT) 35% 0.65 [0.40-1.04] viral load 111 (n) 112 (n) Lilly (RCT) 57% 0.43 [0.28-0.67] symp. case 483 (n) 482 (n) Lilly (RCT) 80% 0.20 [0.08-0.47] symp. case 150 (n) 149 (n) bamlanivimab COVID-19 outcomes c19ly.com Jan 18, 2022 Favors bamlanivimab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit